Do pathologic features predict prognosis in diffuse large B-cell lymphoma?

J. F. Vago, D. D. Weisenburger, James Olen Armitage

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We analyzed 47 immunologically confirmed cases of diffuse large B-cell lymphoma (DLBL) to determine whether the histologic type, surface immunoglobulin (Ig) phenotype, or mitotic rate predicted the clinical outcome. All patients were uniformly staged and uniformly treated with one six-drug protocol. Seventeen cases were subclassified as the noncleaved cell type (DLBL-NC), 23 cases as the immunoblastic type (DLBL-IBL), and 7 cases as other follicular center cell (FCC) types (DLBL-O). The predicted two-year actuarial survival for patients with DLBL-O (82%) was significantly longer than for those with DLBL-NC (35%; p = 0.05). The immunologic phenotype and mitotic rate also predicted the clinical outcome. The predicted two-year survival for patients with DLBL having a surface IgG phenotype (64%) was longer than for those having a surface IgM phenotype (29%; p = 0.06), and the two-year survival for patients with FCC-derived DLBL (DLBL-NC plus DLBL-O) having a surface IgG phenotype (80%) was significantly loger than for those with a surface IgM phenotype (0%; p = 0.02). Similarly, the two-year survival for patients with DLBL having <30 mitoses (68%) was significantly longer than for those having ≥30 mitoses per 10 high-power fields (28%; p = 0.01). These findings are considered preliminary, and additional studies of a large number of similar patients are necessary for their confirmation.

Original languageEnglish (US)
Pages (from-to)217-225
Number of pages9
JournalHematologic Pathology
Volume1
Issue number4
StatePublished - Dec 1 1987

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Phenotype
Survival
Mitosis
Immunoglobulin M
Immunoglobulin G
B-Cell Antigen Receptors
B-Cell Lymphoma

ASJC Scopus subject areas

  • Hematology
  • Pathology and Forensic Medicine

Cite this

Do pathologic features predict prognosis in diffuse large B-cell lymphoma? / Vago, J. F.; Weisenburger, D. D.; Armitage, James Olen.

In: Hematologic Pathology, Vol. 1, No. 4, 01.12.1987, p. 217-225.

Research output: Contribution to journalArticle

Vago, J. F. ; Weisenburger, D. D. ; Armitage, James Olen. / Do pathologic features predict prognosis in diffuse large B-cell lymphoma?. In: Hematologic Pathology. 1987 ; Vol. 1, No. 4. pp. 217-225.
@article{3b186b4991e146318e1f719b519eb0cc,
title = "Do pathologic features predict prognosis in diffuse large B-cell lymphoma?",
abstract = "We analyzed 47 immunologically confirmed cases of diffuse large B-cell lymphoma (DLBL) to determine whether the histologic type, surface immunoglobulin (Ig) phenotype, or mitotic rate predicted the clinical outcome. All patients were uniformly staged and uniformly treated with one six-drug protocol. Seventeen cases were subclassified as the noncleaved cell type (DLBL-NC), 23 cases as the immunoblastic type (DLBL-IBL), and 7 cases as other follicular center cell (FCC) types (DLBL-O). The predicted two-year actuarial survival for patients with DLBL-O (82{\%}) was significantly longer than for those with DLBL-NC (35{\%}; p = 0.05). The immunologic phenotype and mitotic rate also predicted the clinical outcome. The predicted two-year survival for patients with DLBL having a surface IgG phenotype (64{\%}) was longer than for those having a surface IgM phenotype (29{\%}; p = 0.06), and the two-year survival for patients with FCC-derived DLBL (DLBL-NC plus DLBL-O) having a surface IgG phenotype (80{\%}) was significantly loger than for those with a surface IgM phenotype (0{\%}; p = 0.02). Similarly, the two-year survival for patients with DLBL having <30 mitoses (68{\%}) was significantly longer than for those having ≥30 mitoses per 10 high-power fields (28{\%}; p = 0.01). These findings are considered preliminary, and additional studies of a large number of similar patients are necessary for their confirmation.",
author = "Vago, {J. F.} and Weisenburger, {D. D.} and Armitage, {James Olen}",
year = "1987",
month = "12",
day = "1",
language = "English (US)",
volume = "1",
pages = "217--225",
journal = "Hematologic Pathology",
issn = "0886-0238",
publisher = "Marcel Dekker Inc.",
number = "4",

}

TY - JOUR

T1 - Do pathologic features predict prognosis in diffuse large B-cell lymphoma?

AU - Vago, J. F.

AU - Weisenburger, D. D.

AU - Armitage, James Olen

PY - 1987/12/1

Y1 - 1987/12/1

N2 - We analyzed 47 immunologically confirmed cases of diffuse large B-cell lymphoma (DLBL) to determine whether the histologic type, surface immunoglobulin (Ig) phenotype, or mitotic rate predicted the clinical outcome. All patients were uniformly staged and uniformly treated with one six-drug protocol. Seventeen cases were subclassified as the noncleaved cell type (DLBL-NC), 23 cases as the immunoblastic type (DLBL-IBL), and 7 cases as other follicular center cell (FCC) types (DLBL-O). The predicted two-year actuarial survival for patients with DLBL-O (82%) was significantly longer than for those with DLBL-NC (35%; p = 0.05). The immunologic phenotype and mitotic rate also predicted the clinical outcome. The predicted two-year survival for patients with DLBL having a surface IgG phenotype (64%) was longer than for those having a surface IgM phenotype (29%; p = 0.06), and the two-year survival for patients with FCC-derived DLBL (DLBL-NC plus DLBL-O) having a surface IgG phenotype (80%) was significantly loger than for those with a surface IgM phenotype (0%; p = 0.02). Similarly, the two-year survival for patients with DLBL having <30 mitoses (68%) was significantly longer than for those having ≥30 mitoses per 10 high-power fields (28%; p = 0.01). These findings are considered preliminary, and additional studies of a large number of similar patients are necessary for their confirmation.

AB - We analyzed 47 immunologically confirmed cases of diffuse large B-cell lymphoma (DLBL) to determine whether the histologic type, surface immunoglobulin (Ig) phenotype, or mitotic rate predicted the clinical outcome. All patients were uniformly staged and uniformly treated with one six-drug protocol. Seventeen cases were subclassified as the noncleaved cell type (DLBL-NC), 23 cases as the immunoblastic type (DLBL-IBL), and 7 cases as other follicular center cell (FCC) types (DLBL-O). The predicted two-year actuarial survival for patients with DLBL-O (82%) was significantly longer than for those with DLBL-NC (35%; p = 0.05). The immunologic phenotype and mitotic rate also predicted the clinical outcome. The predicted two-year survival for patients with DLBL having a surface IgG phenotype (64%) was longer than for those having a surface IgM phenotype (29%; p = 0.06), and the two-year survival for patients with FCC-derived DLBL (DLBL-NC plus DLBL-O) having a surface IgG phenotype (80%) was significantly loger than for those with a surface IgM phenotype (0%; p = 0.02). Similarly, the two-year survival for patients with DLBL having <30 mitoses (68%) was significantly longer than for those having ≥30 mitoses per 10 high-power fields (28%; p = 0.01). These findings are considered preliminary, and additional studies of a large number of similar patients are necessary for their confirmation.

UR - http://www.scopus.com/inward/record.url?scp=0023498147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023498147&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 217

EP - 225

JO - Hematologic Pathology

JF - Hematologic Pathology

SN - 0886-0238

IS - 4

ER -